Evaluation of Platelet-Rich Plasma (PRP) Versus Topical Minoxidil (5%) in Combination with Oral Finasteride for the Treatment of Androgenic Alopecia
Platelet-Rich Plasma Versus Topical Minoxidil and Finasteride
DOI:
https://doi.org/10.54393/pjhs.v5i08.1666Keywords:
Alopecia, Finasteride, Hair Density, Minoxidil, Platelet-Rich PlasmaAbstract
Androgenic alopecia was an inherited condition leading to gradual thinning and loss of hair on the crown and frontal scalp. Objective: To compare efficacy of PRP and topical minoxidil (5%) when used in addition to oral finasteride for treating androgenic alopecia. Methods: This quasi experimental study was conducted at Dermatology Department of Akhtar Saeed Medical and Dental College Rawalpindi from March 2023 to August 2023. Total 80 patients of both genders (40 in each group) aged 18 to 65 years diagnosed with androgenic alopecia. Participants were divided into two treatment groups: Group A received monthly PRP injections oral finasteride and 1 mg daily, while Group B applied topical minoxidil (5%) twice daily oral finasteride 1 mg daily. Efficacy was labeled as a statistically significant increase in mean hair density of at least 20 hair/cm² from pre-treatment to post-treatment using a trichometer. All participants had baseline demographic factors and clinical data. Data were analyzed using IBM SPSS 27.0. Results: The comparison of mean hair density between Group A (PRP and Finasteride) and Group B (Minoxidil and Finasteride) showed that Group A had a significantly higher mean hair density compared to Group B (101.6 ± 11.2 hair/cm² versus 87.0 ± 9.0 hair/cm², p < 0.001), indicating that the treatment in Group A was more effective. Conclusions: This study found that platelet-rich plasma (PRP) as an addition to oral finasteride improves hair regrowth, density, and patient satisfaction more than PRP combined with topical minoxidil.
References
Heilmann‐Heimbach S, Hochfeld LM, Henne SK, Nöthen MM. Hormonal regulation in male androgenetic alopecia-Sex hormones and beyond: Evidence from recent genetic studies. Experimental Dermatology. 2020 Sep; 29(9): 814-27. doi: 10.1111/exd.14130. DOI: https://doi.org/10.1111/exd.14130
Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R. What's new in therapy for male androgenetic alopecia?. American Journal of Clinical Dermatology. 2023 Jan; 24(1): 15-24. doi: 10.1007/s40257-022-00730-y. DOI: https://doi.org/10.1007/s40257-022-00730-y
He F, Shen M, Zhao Z, Liu Y, Zhang S, Tang Y et al. Epidemiology and disease burden of androgenetic alopecia in college freshmen in China: A population-based study. PLOS One. 2022 Feb; 17(2): e0263912. doi: 10.1371/journal.pone.0263912. DOI: https://doi.org/10.1371/journal.pone.0263912
Kidangazhiathmana A and Santhosh P. Pathogenesis of androgenetic alopecia. Clinical Dermatology Review. 2022 Jul; 6(2): 69-74. doi: 10.4103/cdr.cdr_29_21. DOI: https://doi.org/10.4103/cdr.cdr_29_21
Liu LP, Wariboko MA, Hu X, Wang ZH, Wu Q, Li YM. Factors associated with early-onset androgenetic alopecia: A scoping review. PLOS One. 2024 Mar; 19(3): e0299212. doi: 10.1371/journal.pone.0299212. DOI: https://doi.org/10.1371/journal.pone.0299212
Chen S, Xie X, Zhang G, Zhang Y. Comorbidities in androgenetic alopecia: a comprehensive review. Dermatology and Therapy. 2022 Oct; 12(10): 2233-47. doi: 10.1007/s13555-022-00799-7. DOI: https://doi.org/10.1007/s13555-022-00799-7
Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990-2009. The Journal of Investigative Dermatology. 2014 Apr; 134(4): 1141. doi: 10.1038/jid.2013.464. DOI: https://doi.org/10.1038/jid.2013.464
Rattananukrom T and Suchonwanit P. Are drug treatment strategies really effective against alopecia areata?. Expert Opinion on Pharmacotherapy. 2021 Feb; 22(3): 257-60. doi: 10.1080/14656566.2020.1854728. DOI: https://doi.org/10.1080/14656566.2020.1854728
Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of Cosmetic Dermatology. 2021 Dec; 20(12): 3759-81. doi: 10.1111/jocd.14537. DOI: https://doi.org/10.1111/jocd.14537
Nemane ST, Bhusnure OG, Gholve SB, Mitakari PR, Karwa PN. A Review on Finasteride: A 5-Alpha Reductase Inhibitors, Its Mechanism, Facts and Benefits. Journal of Drug Delivery and Therapeutics. 2019 Jun; 9(3-s): 1132-6. doi: 10.22270/jddt.v9i3-s.3013.
Hillmann K and Blume-Peytavi U. Diagnosis of hair disorders. InSeminars in cutaneous medicine and surgery 2009 Mar; 28(1): 33-38. doi: 10.1016/j.sder.2008.12.005. DOI: https://doi.org/10.1016/j.sder.2008.12.005
Shah KB, Shah AN, Solanki RB, Raval RC. A comparative study of microneedling with platelet-rich plasma plus topical minoxidil (5%) and topical minoxidil (5%) alone in androgenetic alopecia. International Journal of Trichology. 2017 Jan; 9(1): 14-8. doi: 10.4103/ijt.ijt_75_16. DOI: https://doi.org/10.4103/ijt.ijt_75_16
Verma K, Tegta GR, Verma G, Gupta M, Negi A, Sharma R. A study to compare the efficacy of platelet-rich plasma and minoxidil therapy for the treatment of androgenetic alopecia. International Journal of Trichology. 2019 Mar; 11(2): 68-79. doi: 10.4103/ijt.ijt_64_18. DOI: https://doi.org/10.4103/ijt.ijt_64_18
Afzal G, Ahmed N, Zahoor F, Malik T, Farooq O. Efficacy of Platelet-Rich Plasma versus 5% Topical Monixidil for the Treatment of Androgenetic Alopecia. Journal of the College of Physicians and Surgeons Pakistan. 2024 Jan; 34(1): 11-5. doi: 10.29271/jcpsp.2024.01.11. DOI: https://doi.org/10.29271/jcpsp.2024.01.11
Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian Journal of Dermatology, Venereology and Leprology. 2009 Jan; 75: 47. doi: 10.4103/0378-6323.45220. DOI: https://doi.org/10.4103/0378-6323.45220
Shankar DK, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. International Journal of Trichology. 2009 Jan; 1(2): 131-3. doi: 10.4103/0974-7753.58556. DOI: https://doi.org/10.4103/0974-7753.58556
Ruthvik S, John RS, George M, Kumar SP, Krishnan M. Comparison of Efficacy of Platelet-Rich Plasma With and Without Topical Minoxidil for Hair Growth in Patients With Androgenetic Alopecia: A Prospective Study. Cureus. 2024 Feb; 16(2). doi: 10.7759/cureus.53875. DOI: https://doi.org/10.7759/cureus.53875
Elena EP and Irina OS. Combination therapy with platelet-rich plasma and minoxidil leads to better clinical results than monotherapy with these methods in men with androgenetic alopecia. International Journal of Trichology. 2022 Jan; 14(1): 1-7. doi: 10.4103/ijt.ijt_50_19. DOI: https://doi.org/10.4103/ijt.ijt_50_19
Wu S, Liu S, Chen J, Dai D, Liu W, Le D et al. Evaluation of platelet‐rich plasma plus basic fibroblast growth factor combined with minoxidil in the treatment of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology. 2023 Jul; 22(7): 1995-2002. doi: 10.1111/jocd.15825. DOI: https://doi.org/10.1111/jocd.15825
Shah R, Asim M, Ouellette S, Sharif S, Shah A, Rao B. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% topical minoxidil for the treatment of androgenetic alopecia. Journal Drugs Dermatol. 2023 Sep; 22(9): 905-9. doi: 10.36849/JDD.7031.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
